Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Current Assets (2023 - 2025)

Connect Biopharma Holdings' Current Assets history spans 3 years, with the latest figure at $62.6 million for Q3 2025.

  • For Q3 2025, Current Assets changed N/A year-over-year to $62.6 million; the TTM value through Sep 2025 reached $62.6 million, changed N/A, while the annual FY2024 figure was $97.0 million, 2070.35% up from the prior year.
  • Current Assets for Q3 2025 was $62.6 million at Connect Biopharma Holdings, down from $97.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $97.0 million in Q4 2024 and bottomed at -$4.9 million in Q4 2023.
  • The 3-year median for Current Assets is $62.6 million (2025), against an average of $51.5 million.
  • The largest YoY upside for Current Assets was 2070.35% in 2024 against a maximum downside of 2070.35% in 2024.
  • A 3-year view of Current Assets shows it stood at -$4.9 million in 2023, then surged by 2070.35% to $97.0 million in 2024, then crashed by 35.44% to $62.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Current Assets are $62.6 million (Q3 2025), $97.0 million (Q4 2024), and -$4.9 million (Q4 2023).